What is Corvus Pharmaceuticals?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, dedicated to developing and commercializing precisely targeted oncology therapies. The company's strategic focus is on creating medicines for patients battling the most challenging forms of cancer. Its pipeline aims to address unmet medical needs through innovative therapeutic approaches.
How much funding has Corvus Pharmaceuticals raised?
Corvus Pharmaceuticals has raised a total of $244.3M across 4 funding rounds:
Series A
$33.5M
Series B
$75M
Stock Offering
$71M
Stock Offering
$64.8M
Series A (2014): $33.5M with participation from OrbiMed
Series B (2015): $75M led by Fidelity Management and Research Company, Cowen, Blackrock, Cormorant Asset Management, Adams Street Partners, Rock Springs Capital, Sphera Funds Management, OrbiMed, venBio Select, Novo Ventures, Jennison Associates, Roche, and T. Rowe Price
Stock Issuance/Offering (2016): $71M supported by Cowen & Co. and Credit Suisse
Stock Issuance/Offering (2018): $64.8M featuring Credit Suisse and Jefferies Financial Group
Key Investors in Corvus Pharmaceuticals
Fidelity Management and Research Company
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, retirement planning, brokerage, and advisory solutions for individual investors, businesses, employers, and institutions.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
T. Rowe Price
Founded in 1937, T.Rowe Price Group provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. The firm launches and manages equity and fixed income mutual funds and invests in the public equity and fixed income markets globally.
What's next for Corvus Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment indicate Corvus Pharmaceuticals is poised for significant expansion and advancement of its clinical programs. This capital infusion is expected to accelerate the development and commercialization of its oncology therapies, potentially bringing novel treatments to patients with difficult-to-treat cancers. The company's strategic positioning suggests a focus on key milestones in its clinical trials and regulatory pathways, aiming to solidify its market presence in the competitive biopharmaceutical landscape.
See full Corvus Pharmaceuticals company page
